---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-063323"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2021-12-03T23:59:59+00:00"
generated_at: "2026-06-28T03:53:38.672421+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition to restate financials after reclassifying all public shares as temporary equity

## Summary
- Non-reliance on previously issued financial statements from Oct 2020 through Sep 2021 due to share classification error.
- Re-evaluation prompted by SEC comment letter; all public shares now classified as temporary equity.
- Restatements to be filed as amendments to Form 10-Q for Q3 2021 and Form 10-K for 2020.
- Material weakness in internal control over financial reporting identified; remediation plan to be detailed.
- No impact on cash position or trust account established in connection with the IPO.

## SEC filing metadata
- accession: 0001213900-21-063323
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2021-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390021063323/0001213900-21-063323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390021063323/ea151633-8k_helixacq.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-063323
- JSON: https://secwatch.observer/filing/0001213900-21-063323.json
- Plain text: https://secwatch.observer/filing/0001213900-21-063323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.